While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 31.29%, which has investors questioning if this is right time to sell.

However, researchers at the Penn Ovarian Cancer Research Center at the University of Pennsylvania are studying a surprising ...

Equities research analysts at Wedbush boosted their FY2024 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Wednesday, January 29th. Wedbush analyst R.